Insulet Corp
NASDAQ:PODD
Insulet Corp
Operating Income
Insulet Corp
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Insulet Corp
NASDAQ:PODD
|
Operating Income
$220m
|
CAGR 3-Years
62%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Operating Income
$2.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$2.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$4.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$6.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$1.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
See Also
What is Insulet Corp's Operating Income?
Operating Income
220m
USD
Based on the financial report for Dec 31, 2023, Insulet Corp's Operating Income amounts to 220m USD.
What is Insulet Corp's Operating Income growth rate?
Operating Income CAGR 5Y
41%
Over the last year, the Operating Income growth was 485%. The average annual Operating Income growth rates for Insulet Corp have been 62% over the past three years , 41% over the past five years .